Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 4 1Phase 1/2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Prostatic Neoplasms 1Advanced Gastroenteropancreatic Neuroendocrine Tumor 1

Interventions

Carboplatin 129pembrolizumab 124Cisplatin 114Paclitaxel 102Gemcitabine 85Specimen Handling 80Magnetic Resonance Spectroscopy 80Docetaxel 70Dexamethasone 59Cyclophosphamide 59Pemetrexed 55Bevacizumab 54durvalumab 53Doxorubicin 52Radiotherapy 49Capecitabine 49Radiation 47Oxaliplatin 47Fluorouracil 47Rituximab 42Leucovorin 42Vincristine 41Lenalidomide 40Etoposide 38Letrozole 36atezolizumab 35Nivolumab 35Prednisone 31Bortezomib 31130-nm albumin-bound paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Lutetium × 90 days × Clear all
NCT06520345 2026-05-27

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Telix Pharmaceuticals (Innovations) Pty Limited

Phase 3 Recruiting
520 enrolled
Genitourinary

Prostatic Neoplasms

NCT05884255 2026-05-19

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
220 enrolled
EndocrineGastrointestinalNET

Advanced Gastroenteropancreatic Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡